SavedAdd your journal

Journals / Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi / 2021 / Cilt: 11 - Sayı: 3

The Effect of Thyroxine Therapy on Cardiovascular Risk Factors in Patients with Subclinical Hypothyroidism

Subklinik Hipotiroidili Hastalarda Tiroksin Tedavisinin Kardiyovasküler Risk Faktörleri Üzerine Etkisi

Selvihan BEYSEL
Erman ÇAKAL
Mustafa ÖZBEK
Mahmut APAYDIN
Mustafa ÇALIŞKAN
Pages
363–367
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Body mass index (BMI) was high in SH group (32.66±5.57kg/m2) than in control group (25.13±3.20 kg/m2, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Subclinical hypothyroidism (SH) has a deleterious effect on cardiovascular risk factors (CVR); however it shouldbe treated or not is stil controversial.
📊
Key Findings & Data:The aim of our study is to determine CVR in patients with SH, and to investigatethe short term effect of thyroxine treatment on CVR.Material and Methods: Patients with SH (n=30), and age- and sex-matched control group (n=40) were included in thisretrospective study.
💡
Conclusion & Impact:Body mass index (BMI) was high in SH group (32.66±5.57kg/m2) than in control group (25.13±3.20 kg/m2, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Subclinical hypothyroidism (SH) has a deleterious effect on cardiovascular risk factors (CVR); however it shouldbe treated or not is stil controversial. The aim of our study is to determine CVR in patients with SH, and to investigatethe short term effect of thyroxine treatment on CVR.Material and Methods: Patients with SH (n=30), and age- and sex-matched control group (n=40) were included in thisretrospective study. SH patients were treated by 50μg/day thyroxine for 3 months. Pre-treatment CVR was comparedwith post-treatment CVR.Results: Sex distribution and mean age were similar between control (female 66.7%; age 45.76±14.55 years) and SH(female 77.3%; age 45.23±12.02 years) groups (p>0.05). Body mass index (BMI) was high in SH group (32.66±5.57kg/m2) than in control group (25.13±3.20 kg/m2, p

Özet

Amaç: Subklinik hipotiroidizm (SH) kardiyovasküler risk faktörleri (KVR) üzerinde zararlı bir etkiye sahiptir; ancak tedavi edilip edilmemesi halen tartışmalıdır. Çalışmanın amacı, SH hastaların KVR’ini belirlemek ve kısa süreli tiroksin tedavisinin bunlara etkisini araştırmaktır. Gereç ve Yöntemler: Bu retrospektif çalışmaya SH grubu(n=30) ve yaş-cinsiyet eşleştirilmiş kontrol grubu (n=40) dahil edildi. SH hastalarına 3 ay boyunca 50 μg/gün tiroksin tedavisi verildi. Tedaviden önceki KVR, tedaviden sonraki KVR ile karşılaştırıldı. Bulgular: Kontrol (kadın %66,7; yaş 45,76±14,55 yıl) ve SH (kadın %77,3; yaş 45,23±12,02 yıl) grubu arasında, cinsiyet dağılımı ve yaş ortalaması benzerdi (p>0,05). Vücut kitle indeksi (VKİ) SH grubunda (32,66±5,57 kg/m2), kontrol grubundan (25,13±3,20 kg/m2) daha yüksekti. Başlangıçta, SH grubunda serum glukoz (83,76±9,51 vs 91,73± 9,96 mg/dl), toplam kolesterol (162,36±13,41 vs 184,21±51,91 mg/dl), düşük-yoğunluklu lipoprotein-kolesterol (LDLC; 91,73±22,04 vs 104,61±11,36 mg/dl), C-reaktif protein (hs-CRP; 1,53±0,66 vs 2,63±0,93 mg/L) düzeyi, kontrol grubuna göre daha yüksekti (p

🔖

Cite This Article

BEYSEL, S., ÇAKAL, E., ÖZBEK, M., APAYDIN, M., ÇALIŞKAN, M. (2022). The Effect of Thyroxine Therapy on Cardiovascular Risk Factors in Patients with Subclinical Hypothyroidism. Düzce Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, Cilt: 11 - Sayı: 3, 363–367. https://ajindex.com/articles/494664

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Azim S, Nasr C. Subclinical hypothyroidism: When to treat. Cleve Clin J Med. 2019; 86(2): 101-10.
  2. Delitala AP, Fanciulli G, Maioli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med. 2017; 38(1): 17-24.
  3. Abreu IM, Lau E, de Sousa Pinto B, Carvalho D. Subclinical hypothyroidism: to treat or not to treat, that is the question! A systematic review with metaanalysis on lipid profile. Endocr Connect. 2017; 6(3): 188-99.
  4. Yetmiş M, Kazancıoğlu R, Erkoç R, Tükek T, Peru C, Çıkrıkçıoğlu MA. Subklinik hipotiroidili hastalarda lipid profili ve vücut kitle indeksinde değişiklikler; L-tiroksin tedavisinin değerlendirilmesi. Med Bull Haseki. 2011; 49(4): 131-6 5. Bilgir O, Bilgir F, Calan M, Calan OG, Yuksel A. Comparison of pre- and post-levothyroxine highsensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism. Clin Sao Paulo Braz. 2015; 70(2): 97-101.
  5. Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv Endocrinol Metab. 2016; 7(1): 12-23. https://doi.org/ 10.1177/2042018815616543
  6. Güngüneş A, Çelik K, Şahin M, Özbek M, Çakal E, Çakır E et al. Kardiyovasküler risk faktörü olarak fibrinojen, yüksek duyarlılıklı C-reaktif protein ve lipid parametrelerinin subklinik hipotiroidili hastalardaki düzeyi. Turk J Clin Lab. 2016; 7(3).
  7. Suh S, Kim DK. Subclinical hypothyroidism and cardiovascular disease. Endocrinol Metab Seoul Korea. 2015; 30(3): 246-51.
  8. Andersen MN, Olsen AMS, Madsen JC, Kristensen SL, Faber J, Torp-Pedersen C, et al. Long-Term outcome in levothyroxine treated patients with subclinical hypothyroidism and concomitant heart disease. J Clin Endocrinol Metab. 2016; 101(11): 4170-7.
  9. Jiang F, Liu A, Lai Y, Yu X, Li C, Han C, et al. Change in serum TSH levels within the reference range was associated with variation of future blood pressure: A 5-year follow-up study. J Hum Hypertens. 2017; 31(4): 244-7.
  10. Fox CS, Pencina MJ, D’Agostino RB, Murabito JM, Seely EW, Pearce E, et al. Relations of thyroid function to body weight: Cross-sectional and longitudinal observations